Elena M Stoffel1, Erika Koeppe2, Jessica Everett3, Peter Ulintz4, Mark Kiel5, Jenae Osborne3, Linford Williams6, Kristen Hanson3, Stephen B Gruber7, Laura S Rozek8. 1. Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan. Electronic address: estoffel@med.umich.edu. 2. Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan. 3. Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan. 4. BRCF Bioinformatics Core, University of Michigan Medical School, Ann Arbor, Michigan. 5. Genomenon Inc, Ann Arbor, Michigan. 6. Rackham Graduate School, University of Michigan, Ann Arbor, Michigan. 7. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California. 8. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
Abstract
BACKGROUND & AIMS: The incidence of colorectal cancer (CRC) in individuals younger than 50 years is increasing. We sought to ascertain the proportion of young CRC cases associated with genetic predisposition. METHODS: We performed a retrospective study of individuals diagnosed with CRC at an age younger than 50 years, evaluated by the clinical genetics service at a single tertiary care cancer center from 1998 through 2015. We collected data on patient histories, tumor phenotypes, and results of germline DNA sequencing. For subjects with uninformative clinical evaluations, germline DNA samples were (re)sequenced using a research-based next-generation sequencing multigene panel. The primary outcome was identification of a pathogenic germline mutation associated with cancer predisposition. RESULTS: Of 430 young CRC cases, 111 (26%) had a first-degree relative with CRC. Forty-one of the subjects with CRC (10%) had tumors with histologic evidence for mismatch repair deficiency. Of 315 subjects who underwent clinical germline sequencing, 79 had mutations associated with a hereditary cancer syndrome and 21 had variants of uncertain significance. Fifty-six subjects had pathogenic variants associated with Lynch syndrome (25 with mutations in MSH2, 24 with mutations in MLH1, 5 with mutations in MSH6, and 2 with mutations in PMS2) and 10 subjects had pathogenic variants associated with familial adenomatous polyposis. Thirteen subjects had mutations in other cancer-associated genes (8 in MUTYH, 2 in SMAD4, 1 in BRCA1, 1 in TP53, and 1 in CHEK2), all identified through multigene panel tests. Among 117 patients with uninformative clinical evaluations, next-generation sequence analysis using a multigene panel detected actionable germline variants in 6 patients (5%). Only 43 of the 85 subjects with germline mutations associated with a hereditary cancer syndrome (51%) reported a CRC diagnosis in a first-degree relative. CONCLUSIONS: Approximately 1 in 5 individuals diagnosed with CRC at age younger than 50 years carries a germline mutation associated with cancer; nearly half of these do not have clinical histories typically associated with the identified syndrome. Germline testing with multigene cancer panels should be considered for all young patients with CRC.
BACKGROUND & AIMS: The incidence of colorectal cancer (CRC) in individuals younger than 50 years is increasing. We sought to ascertain the proportion of young CRC cases associated with genetic predisposition. METHODS: We performed a retrospective study of individuals diagnosed with CRC at an age younger than 50 years, evaluated by the clinical genetics service at a single tertiary care cancer center from 1998 through 2015. We collected data on patient histories, tumor phenotypes, and results of germline DNA sequencing. For subjects with uninformative clinical evaluations, germline DNA samples were (re)sequenced using a research-based next-generation sequencing multigene panel. The primary outcome was identification of a pathogenic germline mutation associated with cancer predisposition. RESULTS: Of 430 young CRC cases, 111 (26%) had a first-degree relative with CRC. Forty-one of the subjects with CRC (10%) had tumors with histologic evidence for mismatch repair deficiency. Of 315 subjects who underwent clinical germline sequencing, 79 had mutations associated with a hereditary cancer syndrome and 21 had variants of uncertain significance. Fifty-six subjects had pathogenic variants associated with Lynch syndrome (25 with mutations in MSH2, 24 with mutations in MLH1, 5 with mutations in MSH6, and 2 with mutations in PMS2) and 10 subjects had pathogenic variants associated with familial adenomatous polyposis. Thirteen subjects had mutations in other cancer-associated genes (8 in MUTYH, 2 in SMAD4, 1 in BRCA1, 1 in TP53, and 1 in CHEK2), all identified through multigene panel tests. Among 117 patients with uninformative clinical evaluations, next-generation sequence analysis using a multigene panel detected actionable germline variants in 6 patients (5%). Only 43 of the 85 subjects with germline mutations associated with a hereditary cancer syndrome (51%) reported a CRC diagnosis in a first-degree relative. CONCLUSIONS: Approximately 1 in 5 individuals diagnosed with CRC at age younger than 50 years carries a germline mutation associated with cancer; nearly half of these do not have clinical histories typically associated with the identified syndrome. Germline testing with multigene cancer panels should be considered for all young patients with CRC.
Authors: Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt Journal: Am J Gastroenterol Date: 2015-02-03 Impact factor: 10.864
Authors: Carlos J Gallego; Brian H Shirts; Caroline S Bennette; Greg Guzauskas; Laura M Amendola; Martha Horike-Pyne; Fuki M Hisama; Colin C Pritchard; William M Grady; Wylie Burke; Gail P Jarvik; David L Veenstra Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Maureen E Mork; Y Nancy You; Jun Ying; Sarah A Bannon; Patrick M Lynch; Miguel A Rodriguez-Bigas; Eduardo Vilar Journal: J Clin Oncol Date: 2015-07-20 Impact factor: 44.544
Authors: Zaid M Abdelsattar; Sandra L Wong; Scott E Regenbogen; Diana M Jomaa; Karin M Hardiman; Samantha Hendren Journal: Cancer Date: 2016-01-25 Impact factor: 6.860
Authors: Rachel Pearlman; Wendy L Frankel; Benjamin Swanson; Weiqiang Zhao; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Christopher Bigley; Lori Nelsen; Paul J Goodfellow; Richard M Goldberg; Electra Paskett; Peter G Shields; Jo L Freudenheim; Peter P Stanich; Ilene Lattimer; Mark Arnold; Sandya Liyanarachchi; Matthew Kalady; Brandie Heald; Carla Greenwood; Ian Paquette; Marla Prues; David J Draper; Carolyn Lindeman; J Philip Kuebler; Kelly Reynolds; Joanna M Brell; Amy A Shaper; Sameer Mahesh; Nicole Buie; Kisa Weeman; Kristin Shine; Mitchell Haut; Joan Edwards; Shyamal Bastola; Karen Wickham; Karamjit S Khanduja; Rosemary Zacks; Colin C Pritchard; Brian H Shirts; Angela Jacobson; Brian Allen; Albert de la Chapelle; Heather Hampel Journal: JAMA Oncol Date: 2017-04-01 Impact factor: 31.777
Authors: Aung Ko Win; Mark A Jenkins; James G Dowty; Antonis C Antoniou; Andrew Lee; Graham G Giles; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Dennis J Ahnen; Stephen N Thibodeau; Graham Casey; Steven Gallinger; Loïc Le Marchand; Robert W Haile; John D Potter; Yingye Zheng; Noralane M Lindor; Polly A Newcomb; John L Hopper; Robert J MacInnis Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-10-31 Impact factor: 4.254
Authors: Sigurdis Haraldsdottir; Thorunn Rafnar; Wendy L Frankel; Sylvia Einarsdottir; Asgeir Sigurdsson; Heather Hampel; Petur Snaebjornsson; Gisli Masson; Daniel Weng; Reynir Arngrimsson; Birte Kehr; Ahmet Yilmaz; Stefan Haraldsson; Patrick Sulem; Tryggvi Stefansson; Peter G Shields; Fridbjorn Sigurdsson; Tanios Bekaii-Saab; Pall H Moller; Margret Steinarsdottir; Kristin Alexiusdottir; Megan Hitchins; Colin C Pritchard; Albert de la Chapelle; Jon G Jonasson; Richard M Goldberg; Kari Stefansson Journal: Nat Commun Date: 2017-05-03 Impact factor: 14.919
Authors: Peter Broderick; Sara E Dobbins; Daniel Chubb; Ben Kinnersley; Malcolm G Dunlop; Ian Tomlinson; Richard S Houlston Journal: Gastroenterology Date: 2016-10-03 Impact factor: 22.682
Authors: Anne M L Jansen; Pradipta Ghosh; Tikam C Dakal; Thomas P Slavin; C Richard Boland; Ajay Goel Journal: Fam Cancer Date: 2019-09-25 Impact factor: 2.375
Authors: Eric E Low; Joshua Demb; Lin Liu; Ashley Earles; Ranier Bustamante; Christina D Williams; Dawn Provenzale; Tonya Kaltenbach; Andrew J Gawron; Maria Elena Martinez; Samir Gupta Journal: Gastroenterology Date: 2020-01-09 Impact factor: 22.682